NASDAQ:NLTXNeoleukin Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neoleukin Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.93 -1.00 (-7.18 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$12.90Now: $12.93▼$13.9050-Day Range$12.10MA: $13.94▼$17.0552-Week Range$2.37Now: $12.93▼$18.13Volume328,000 shsAverage Volume402,085 shsMarket Capitalization$496.33 millionP/E RatioN/ADividend YieldN/ABeta-4.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNeoleukin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Neoleukin Therapeutics has a potential upside of 66.3% from its current price of $12.93.Amount of Analyst CoverageNeoleukin Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.5 Community Rank Outperform VotesNeoleukin Therapeutics has received 31 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeoleukin Therapeutics has received 72 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeoleukin Therapeutics has received 69.90% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neoleukin Therapeutics and other stocks. Vote “Outperform” if you believe NLTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NLTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeoleukin Therapeutics does not currently pay a dividend.Dividend GrowthNeoleukin Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neoleukin Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Neoleukin Therapeutics is held by insiders.Percentage Held by Institutions59.29% of the stock of Neoleukin Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Neoleukin Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neoleukin Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neoleukin Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoleukin Therapeutics has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 1.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NLTX Previous Symbol CUSIPN/A CIKN/A Webwww.neoleukin.com Phone206-732-2133Debt Debt-to-Equity Ratio0.08 Current Ratio24.92 Quick Ratio24.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25 million Price / Sales19.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book4.44Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-69,440,000.00 Net MarginsN/A Return on Equity-26.95% Return on Assets-25.39%Miscellaneous Employees8 Outstanding Shares38,386,000Market Cap$496.33 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:NLTX Rates by TradingView Receive NLTX News and Ratings via Email Sign-up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions How has Neoleukin Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NLTX stock has increased by 62.4% and is now trading at $12.93. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Neoleukin Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neoleukin Therapeutics. When is Neoleukin Therapeutics' next earnings date? Neoleukin Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Neoleukin Therapeutics. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics (NASDAQ:NLTX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. View Neoleukin Therapeutics' earnings history. What price target have analysts set for NLTX? 6 Wall Street analysts have issued 12-month price targets for Neoleukin Therapeutics' shares. Their forecasts range from $18.00 to $28.00. On average, they expect Neoleukin Therapeutics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price. View analysts' price targets for Neoleukin Therapeutics. Has Neoleukin Therapeutics been receiving favorable news coverage? News coverage about NLTX stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neoleukin Therapeutics earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Neoleukin Therapeutics. Who are some of Neoleukin Therapeutics' key competitors? Some companies that are related to Neoleukin Therapeutics include Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Xencor (XNCR), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), I-Mab (IMAB), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Epizyme (EPZM) and Akebia Therapeutics (AKBA). View all competitors. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Calithera Biosciences (CALA), Canopy Growth (CGC), Intra-Cellular Therapies (ITCI), InVitae (NVTA), ACADIA Pharmaceuticals (ACAD), Athenex (ATNX), Five Prime Therapeutics (FPRX), Gilead Sciences (GILD), ImmunoGen (IMGN) and Pfizer (PFE). Who are Neoleukin Therapeutics' key executives? Neoleukin Therapeutics' management team includes the following people: Mr. David J. Main, Co-Founder, Chairman & Pres (Age 54)Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)Dr. Jonathan G. Drachman, Chief Exec. Officer (Age 57)Ms. Shelley McCloskey, VP of HR & Admin. (Age 59) What is Neoleukin Therapeutics' stock symbol? Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX." How do I buy shares of Neoleukin Therapeutics? Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neoleukin Therapeutics' stock price today? One share of NLTX stock can currently be purchased for approximately $12.93. How big of a company is Neoleukin Therapeutics? Neoleukin Therapeutics has a market capitalization of $496.33 million and generates $25 million in revenue each year. The company earns $-69,440,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Neoleukin Therapeutics employs 8 workers across the globe. What is Neoleukin Therapeutics' official website? The official website for Neoleukin Therapeutics is www.neoleukin.com. How can I contact Neoleukin Therapeutics? Neoleukin Therapeutics' mailing address is SUITE 360 - 1616 EASTLAKE AVE EAST, SEATTLE WA, 98102. The company can be reached via phone at 206-732-2133 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
